Search research articles
Contact Us
Filters
Showing results (171-180 of 183) with videos related to
Page
of 19
Sort By:
EMBO Molecular Medicine
|
September 7, 2022
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity
Gökhan Güner, Marlene Aßfalg, Kai Zhao, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
October 16, 2024
The long non-coding RNA NEAT1 contributes to aberrant STAT3 signaling in pancreatic cancer and is regulated by a metalloprotease-disintegrin ADAM8/miR-181a-5p axis
Yutong Gao, Kimia Zandieh, Kai Zhao, et al.
ACS Infectious Diseases
|
April 11, 2020
Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus
Nicole Pribut, Thomas M Kaiser, Robert J Wilson, et al.
Cells
|
April 12, 2024
A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
Kai Zhao, Madita Braun, Leonie Meyer, et al.
The Journal of Biological Chemistry
|
September 30, 2011
ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein
Marcia L Moss, Gary Powell, Miles A Miller, et al.
Scientific Reports
|
September 17, 2017
Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression
Kosta Theodorou, Emiel P C van der Vorst, Marion J Gijbels, et al.
Cell Reports
|
November 23, 2017
Mucus Detachment by Host Metalloprotease Meprin β Requires Shedding of Its Inactive Pro-form, which Is Abrogated by the Pathogenic Protease RgpB
Rielana Wichert, Anna Ermund, Stefanie Schmidt, et al.
Nature Communications
|
January 29, 2015
ADAM8 as a drug target in pancreatic cancer
Uwe Schlomann, Garrit Koller, Catharina Conrad, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2023
Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M<sup>pro</sup> Inhibitors
Leon Jacobs, Aletta van der Westhuyzen, Nicole Pribut, et al.
Cell Reports
|
November 14, 2019
Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome
Katherine A Waugh, Paula Araya, Ahwan Pandey, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 183) with videos related to
Sort By:
Page
of 19
EMBO Molecular Medicine
|
September 7, 2022
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity
Gökhan Güner, Marlene Aßfalg, Kai Zhao, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
October 16, 2024
The long non-coding RNA NEAT1 contributes to aberrant STAT3 signaling in pancreatic cancer and is regulated by a metalloprotease-disintegrin ADAM8/miR-181a-5p axis
Yutong Gao, Kimia Zandieh, Kai Zhao, et al.
ACS Infectious Diseases
|
April 11, 2020
Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus
Nicole Pribut, Thomas M Kaiser, Robert J Wilson, et al.
Cells
|
April 12, 2024
A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
Kai Zhao, Madita Braun, Leonie Meyer, et al.
The Journal of Biological Chemistry
|
September 30, 2011
ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein
Marcia L Moss, Gary Powell, Miles A Miller, et al.
Scientific Reports
|
September 17, 2017
Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression
Kosta Theodorou, Emiel P C van der Vorst, Marion J Gijbels, et al.
Cell Reports
|
November 23, 2017
Mucus Detachment by Host Metalloprotease Meprin β Requires Shedding of Its Inactive Pro-form, which Is Abrogated by the Pathogenic Protease RgpB
Rielana Wichert, Anna Ermund, Stefanie Schmidt, et al.
Nature Communications
|
January 29, 2015
ADAM8 as a drug target in pancreatic cancer
Uwe Schlomann, Garrit Koller, Catharina Conrad, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2023
Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M<sup>pro</sup> Inhibitors
Leon Jacobs, Aletta van der Westhuyzen, Nicole Pribut, et al.
Cell Reports
|
November 14, 2019
Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome
Katherine A Waugh, Paula Araya, Ahwan Pandey, et al.
Page
of 19